Article Details
Retrieved on: 2022-03-01 07:46:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
AstraZeneca Plc said on Tuesday it had agreed with Swiss biotechnology firm Neurimmune to develop an antibody-based therapy for a rare, ...
Article found on: www.reuters.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here